CI · Q2 2025 Earnings
NeutralCigna
Reported July 31, 2025
30-second summary
Revenue grew 11% YoY to $67.2B, driven by Evernorth's 17% growth, while Cigna Healthcare revenue fell 18% YoY to $10.8B reflecting the Medicare Advantage divestiture. Management reaffirmed FY2025 adjusted EPS guidance of at least $29.60 and held the Medical Care Ratio at 83.2% — the low end of the 83.2%–84.2% guided range. Elevated stop-loss costs persisted in line with expectations.
Headline numbers
EPS
Q2 FY2025
$7.20
Revenue
Q2 FY2025
$67.18B
+11.0% YoY
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $67.18B | +11.0% |
| EPS | $7.20 | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Evernorth Health Services | $57.825B | +17.0% |
| Pharmacy Benefit Services | $31.954B | +20.0% |
| Specialty and Care Services | $25.871B | +13.0% |
| Cigna Healthcare | $10.754B | -18.0% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Total Pharmacy Customers | 121.9 million |
| Total Medical Customers | 18.0 million |
| Total Customer Relationships | 182.2 million |
| Cigna Healthcare Medical Care Ratio | 83.2% |
| Evernorth Health Services Margin | 2.9% |
| Cigna Healthcare Margin | 10.2% |
| SG&A Expense Ratio (GAAP) | 5.1% |
| Adjusted SG&A Expense Ratio | 4.9% |
Management tone
Without transcript prepared-remarks coverage of a comparison period, a tone shift assessment isn't possible. The Q&A and prepared remarks signaled two operational throughlines worth flagging:
The integrated medical-plus-pharmacy pitch hardened. On the UBS question, David quantified aggregate pharmacy as in the mid-20s as a percentage of total medical costs (vs. 10–12% a decade ago) and headed toward a 30% slice in short order, with specialty drugs alone at 20% of an average employer's total cost of care per Brian. The pitch: only Cigna can track patients longitudinally across both medical and pharmacy benefits — a specialty injectable starting in the medical benefit that transitions to a self-injectable under the drug benefit. This is the affirmative case for why MCR is being held while peers struggle.
Regulatory posture is combative on PBM legislation. On Arkansas, David emphasized the temporary restraining order and said the legislation arbitrarily constrains access, would break continuity of care, would restrict choice, and would have a negative impact on affordability. No concessions, no softening — Cigna is fighting the precedent while reiterating a public-private partnership orientation more broadly.
Q&A highlights
AJ Rice · UBS
How is Cigna using Evernorth's PBM and pharmacy services insights to gain competitive advantage in commercial markets and ASO insurance, particularly given elevated drug cost trends? What is the magnitude of this advantage versus competitors like Blue Cross?
David and Brian explained that pharmacy services now represent 25%+ of total medical costs (vs. 10-12% a decade ago) and are growing toward 30%. The integrated model allows Cigna to track patient care journeys across medical and pharmacy benefits longitudinally. They can see specialty injectables transition from medical to drug benefit and manage the whole person including mental health, which competitors without integrated platforms cannot do. This integration has been instrumental in managing Cigna Healthcare MCR to committed levels.
Lisa Gill · JPMorgan
What is the 2026 selling season outlook across pharmacy benefit services and Cigna Healthcare? What are client priorities and competitive dynamics? How is Cigna responding to Arkansas PBM legislation and broader regulatory/legislative PBM pressures?
Brian outlined strong PBM retention tracking mid-90s for 2026. Prime Therapeutics renewal finalized as example of large client confidence. Cigna Healthcare maintaining share in flat/shrinking national account market; net share winner in select under-500 segment. Key market themes: affordability #1 priority, personalization of benefits/networks, consolidation of point solutions. Longer decision timelines observed among larger employers. David addressed Arkansas: Cigna pleased with temporary restraining order blocking legislation; emphasized legislation would arbitrarily constrain access, break care continuity, restrict choice, and increase costs. Advocated for sustainable affordability through choice and innovation, not arbitrary constraints. Commitment to continued engagement at state and federal level.
Justin Lake · Wolf Research
What impact is more sophisticated hospital billing and coding (leveraging AI) having on commercial trend? Is stop-loss disproportionately affected? How are employers responding to double-digit rate increases?
David confirmed elevated billing sophistication using AI is occurring and impacting costs; Cigna is countering through its own AI/technology capabilities and provider contracting. Noted affordability pressure is industry-wide (federal, state, employers, individuals). Rising decision-making criteria in C-suite opening door to more innovative solutions. Brian noted stop-loss premiums grew 13% in Q2, business recovering margin profile over next two renewal cycles. Revised cost structure reflected in later 2025 renewals; sold rate increases for post-January renewals significantly higher than January increases. Two-thirds of portfolio renews Jan 1. Sophisticated billing does not have outsized impact on stop-loss specifically. Performance broadly in line with expectations.
Charles Reed · TD Cowen
What is the market structure for CuraScript specialty distribution to health systems? Who are the incumbents? Does Cigna compete with traditional drug distributors like McKesson or Sankora? What is the biosimilar opportunity (Stelara, Humira) and how does Qualant fit in?
Brian detailed CuraScript as $25B business growing double-digit annually, focused on provider/medical-benefit specialty (40% of $400B+ market). Distinct from wholesaler competitors (McKesson, Sankora) which focus on pharmacy-benefit side where CuraScript has minimal volume. Cigna's value prop is distribution plus enablement services (clinical coordination, inventory management). Health systems seeking margin alternatives as core business margins compress. Biosimilar opportunity: $100B of specialty drug spend subject to biosimilar/generic competition by 2030. Launched $0 OOP Stelara biosimilar in May with encouraging early returns; gradual growth expected through year-end, contemplated in Evernorth outlook. CuraScript is distribution vehicle for Aqualent biosimilars to health systems.
Kevin Fishbeck · Bank of America
How does Cigna's competitive positioning differ from peers (referencing competitor under-earning comments)? What is Cigna seeing in commercial pricing environment and competitive dynamics? Are margins pressured differently across subsegments?
Brian characterized market as firm/rational on pricing with limited appetite for undercutting. Cigna's 2026 pricing assumptions assume continued elevated cost trends; expectations are for price increases exceeding 2025 levels (which were already high). Most employer business is self-funded/experience-rated, not block-rated, limiting exposure to broad market rate pressure. Anne added that Cigna Healthcare businesses generally performing in target margin ranges, with two exceptions: exchange business running below target (utilization pressure) and stop-loss recovering toward run-rate through 2026-2027. Specialty injectables
What to watch into next quarter
Cigna Healthcare MCR trajectory — Q2 landed at 83.2%, the floor of the FY 83.2%–84.2% guide. Management said Q3 will be toward the upper end of the full-year range on typical seasonality. Watch whether Q3 stays within that frame or breaches the 84.2% ceiling, which would signal cost trend is breaking through the integrated-care defense.
PBM retention for 2026 — Management said mid-90s-or-better tracking; watch for confirmation or any deterioration by the Q3 call, when the 2026 selling season is largely closed.
Individual exchange repricing for 2026 — Cigna is refiling for further price increases and continues to prioritize margin over growth. Watch for any indication of footprint or pricing finalization on the Q3 call.
Arkansas PBM legislation and broader state regulatory expansion — The TRO is in place but the legislative trajectory matters. Watch for similar bills in other states and any change in language from management about engagement outcomes.
Stelara biosimilar and broader biosimilar adoption — Specialty and Care Services earnings reflected ongoing biosimilar adoption; watch for any concrete adoption metrics on the Q3 call.
Sources
- Cigna Q2 2025 press release (SEC EX-99.1): https://www.sec.gov/Archives/edgar/data/1739940/000114036125028099/ef20052574_ex99-1.htm
- Cigna Q2 2025 earnings call Q&A transcript excerpts
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.